AmMax Bio Announces the Appointment of Biotechnology Executive, Michael Kavanaugh, M.D., as Independent Board Member
24 févr. 2022 08h30 HE
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics targeting the...
AmMax Bio Hosting Key Opinion Leader Webinar on AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
30 nov. 2021 08h00 HE
|
AmMax Bio, Inc.
Forging a New Standard of Care in TGCT: Intra-Articular Administration of AMB-05X Tuesday, December 7th @ 1pm ET REDWOOD CITY, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”),...
AmMax Bio Announces Positive Interim Phase 2 Results of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
20 oct. 2021 08h00 HE
|
AmMax Bio, Inc.
Intra-articular (IA) Delivery of AMB-05X Demonstrates Proof-of-Concept in TGCT With A Rapid Onset of Tumor Reduction in All Patients Within Six Weeks Interim AMB-05X Data Support Potential for...
AmMax Bio to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium
14 juil. 2021 08h00 HE
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing novel treatments with AMB-05X, its proprietary...
AmMax Bio Announces First Patient Enrolled in Phase 2 Trial of AMB-05X For Tenosynovial Giant Cell Tumor (TGCT)
26 mai 2021 08h00 HE
|
AmMax Bio, Inc.
Novel Intra-articular Drug Delivery to Minimize Systemic Toxicity Associated with Currently Available TGCT Therapies First Set of Patient Data Expected in Second Half of 2021 REDWOOD CITY,...
AmMax Bio to Present at the BofA Securities 2021 Virtual Healthcare Conference
29 avr. 2021 16h01 HE
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company focused on developing novel treatments with AMB-05X, its...